[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625314":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":45,"id":52,"slug":19,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":19,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":78,"whyStopped":19,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Copenhagen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ATR-258","EXPERIMENTAL","Daily oral ATR-258",[13],"Drug: ATR-258",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Daily oral ATR-258 for 8 weeks with repeated experimental assessment days (Days 1, 15, 29, 56).",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Morten Hostrup, PhD, MD","CONTACT","+45 24474785","mhostrup@nexs.ku.dk",[27],{"facility":28,"status":19,"city":29,"state":19,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"University of Copenhagen, August Krogh Section for Human & Molecular Physiology","Copenhagen","2100","Denmark",{"type":33,"coordinates":34},"Point",[35,36],12.56553,55.67594,{"lat":36,"lon":35},[39],{"name":40,"role":23,"phone":19,"phoneExt":19,"email":25},"Morten Hostrup",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"SPONSOR_INVESTIGATOR","Morten Hostrup, PhD","Associate Professor, MD",[46,49,50],{"name":47,"class":48},"Atrogi AB","INDUSTRY",{"name":5,"class":6},{"name":51,"class":6},"Stockholm University","100625314",false,"NCT07421024","Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle","Biased G Protein-Coupled Receptor Kinase Signaling Via β2-Adrenergic Receptors and Downstream Activation of Protein Synthesis-Regulating Kinases and Receptor Desensitization in Human Skeletal Muscle","ATR","Inclusion Criteria:\n\n* Healthy men\n* Age 21-45 years\n* BMI 25-35 kg\u002Fm\\^2\n* Body fat percentage 25-40%\n* Lean Mass Index 14-22\n\nExclusion Criteria:\n\n* Regular use of or allergy to β2-agonists\n* Serious adverse reactions to β2-agonists\n* Current smoker\n* Regular use of medication (except OTC allergy or analgesics)\n* Abnormal ECG before or after β2-AR stimulation\n* Hypertension\n* Reduced kidney function (eGFR \\\u003C 90 ml\u002Fmin\u002F1.73m\\^2)\n* Cardiovascular, metabolic, gastrointestinal, renal, or pulmonary disease\n* Psychiatric or neurological disorders affecting compliance\u002Fsafety reporting\n* Cancer history within the last 5 years\n* Substance abuse or alcohol intake \\>14 units\u002Fweek",true,"MALE","21 Years","45 Years",{"count":64,"type":65},10,"ESTIMATED","INTERVENTIONAL",[68],"PHASE2","This longitudinal mechanistic physiological study examines biased β2-adrenergic receptor (β2-AR) signaling in human skeletal muscle, with emphasis on G protein-coupled receptor kinase (GRK)-mediated pathways. Participants will receive daily oral dosing of the GRK-selective long-acting β2-agonist ATR-258 for 8 weeks. Muscle biopsies and physiological measurements will quantify GRK-, cAMP\u002FPKA-, and β-arrestin-related signaling, fiber-type specificity, and potential receptor desensitization with repeated stimulation.",[71],"Overweight and Obesity",[73,74,75,76,77],"beta2","muscle","atr-258","adrenergic","biased signaling","NOT_YET_RECRUITING","2026-02-16",{"date":81,"type":82},"2026-02-19","ACTUAL",{"date":84,"type":65},"2026-02-20",{"date":86,"type":65},"2026-12-31",{"name":43,"class":6},1]